ClinConnect ClinConnect Logo
Search / Trial NCT04249414

Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography

Launched by DRÄGERWERK AG & CO. KGAA · Jan 29, 2020

Trial Information

Current as of May 20, 2025

Suspended

Keywords

Ventilation Monitoring Electrical Impedance Tomography Perfusion Monitoring Hemodynamic Monitoring

ClinConnect Summary

The results of this study will help defining the capability and reliability of PulmoVista® 500 (PV500) to detect changes in both global and regional ventilation and perfusion. As this is a non-invasive, observational trial, neither a positive nor a negative impact on the actual study participants is expected. The results will, however, improve the knowledge about the electrical impedance tomography (EIT) technology and thus aid the use of this technology for the benefit of future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18 - 80 years
  • Mandatorily ventilated intensive-care patients with impairment in oxygenation (P/F ratio \< 300 at PEEP ≥ 5) ventilated at a positive end-expiratory pressure (PEEP) not exceeding 10 mbar and an fraction of inspired oxygen (FiO2) chosen, such that pulse oximetry is sensitive towards arterial oxygen pressure (PaO2) changes.
  • Expected ventilation time \>48h
  • Existing central venous and arterial access
  • Chest circumference 70 - 150 cm
  • Mandatory mechanical ventilation (patients without spontaneous efforts)
  • Serum levels of sodium and chloride within normal range
  • Cardiac output monitoring in place (PICCO)
  • Exclusion Criteria:
  • Contraindication to central venous injection of 5 % sodium chloride (NaCl) (e.g. elevated Na+ and/or Cl- concentration: Na+ should not exceed 150 mmol/l, Chloride should not exceed 115 mmol/l, known hypernatremia, known high serum osmolality)
  • * Contraindications of PulmoVista 500:
  • Patients with pacemakers, defibrillators or other electrically active implants
  • Patients with damaged skin or impaired skin contact of the electrodes due to wound dressings
  • Patients where the attachment of the patient belt could pose a risk to the patient, e.g. patients with spinal lesions or fractures
  • Patients with uncontrolled body movements
  • Extremely obese patients (BMI\>50)
  • Patients during pregnancy
  • Patients with massive lung edema
  • Use during electricity-based therapies, such as electrosurgery or electrocautery
  • Use in the presence of strong magnetic fields
  • Use in conjunction with other bioimpedance measurement devices
  • Infection or colonization with multi-resistant pathogens that require isolation of the patient (e.g. MRSA)

About Drägerwerk Ag & Co. Kgaa

Drägerwerk AG & Co. KGaA is a global leader in medical and safety technology, dedicated to enhancing patient care and ensuring occupational safety. With a rich heritage dating back to 1889, the company specializes in innovative solutions for critical care, anesthesia, and respiratory support, as well as advanced monitoring and diagnostic systems. Committed to research and development, Drägerwerk collaborates with healthcare professionals and institutions to advance clinical practices and improve outcomes. Their robust portfolio of products and services reflects a steadfast commitment to quality, reliability, and technological excellence in the healthcare sector.

Locations

Göttingen, , Germany

Patients applied

0 patients applied

Trial Officials

Onnen Mörer, Prof. Dr.

Principal Investigator

Centre of Anaesthesiology University Medical Center Göttingen

Michael Quintel, Prof. Dr.

Study Director

Centre of Anaesthesiology University Medical Center Göttingen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials